A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC)

Trial Profile

A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms Precision-UC
  • Sponsors Tillotts Pharma
  • Most Recent Events

    • 11 Nov 2017 According to a Tillotts Pharma media release, this trial was led by Prof. Geert D Haens, University of Amsterdam.
    • 11 Nov 2017 According to a Tillotts Pharma media release, full results were published in the international journal Alimentary Pharmacology & Therapeutics.
    • 01 Aug 2017 Primary endpoint has been met. (Clinical and endoscopic remission) as per results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top